Home›Trial›NCT06040541
NCT06040541Phase 1RECRUITING

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Study Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors
Interventions / Drugs
RMC-9805RMC-6236
View on ClinicalTrials.gov ↗
Sponsor
RVMD
Revolution Medicines
Precision Oncology
D36/100
Study Details
Enrollment604 participants
Primary Completion—
Lead SponsorRevolution Medicines, Inc.
Data Retrieved2026-04-11 04:26:28.070702+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 604 participants
Sponsor Catalyst Profile

Revolution Medicines (RVMD) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

RVMD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.